Polycythemia vera is a blood cancer that makes too much blood. Standard care for most patients is to take blood out of them, over and over, for years. On August 28 the FDA approved the first drug of its kind for the disease. It works the other way: a weekly injection that tells the marrow to slow production.
In phase 3 VERIFY, 76.9% of treated patients needed no phlebotomy between weeks 20 and 32, versus 32.9% on placebo; mean phlebotomies fell from 1.8 to 0.5 per patient.
Protagonist Therapeutics discovered the peptide and led it through phase 3; Takeda holds exclusive global commercialization rights. The same mechanism is in trials for hereditary hemochromatosis.
TIMELINE: rusfertide — from hormone to approval
─────────────────────────────────────────────────────────────
2001 ──── 2014 ──── 2021 ──── Mar 2025 ──── Jan 2026 ──── Aug 2026
🔬 🔬 🧪 📊 📋 ◉ NOW
hepcidin PTG-300 Breakthr. VERIFY NDA FDA
mapped designed therapy topline submitted approval
designation readout + priority
review
🔥 NEXT: commercial launch · hemochromatosis expansion
Chronology: Protagonist Therapeutics releases, FDA.
The drug copies hepcidin, the hormone that decides how much iron reaches the bone marrow. Give it weekly and the marrow runs short of iron for new red cells. It is phlebotomy in a syringe.
Phlebotomy-free patients on Mimrylo
Patients on rusfertide plus standard of care who needed no phlebotomy between weeks 20 and 32 in phase 3 VERIFY, versus 32.9% on placebo. · FDA/Takeda, 2026
The disease that runs on too much blood
Polycythemia vera belongs to a family of marrow diseases driven by a single acquired mutation, usually in the JAK2 gene. The result is erythrocytosis: too many red cells, thicker blood, and a higher risk of stroke, deep-vein thrombosis and pulmonary embolism. For a patient usually diagnosed in their sixties, that clot risk is the thing that kills.
Phlebotomy remains the backbone of care. Remove 400 to 500 ml of blood until hematocrit, the share of blood made of red cells, drops below 45%. Repeat when it creeps back. It works, and it has a running cost: clinic time, shrinking veins, and a slow depletion of iron stores. Many PV patients end up iron-deficient on lab tests while still overproducing red cells. The disease looks like a contradiction until you see the mechanism underneath.
Drugs such as hydroxyurea, interferons and ruxolitinib add cytoreduction. They do not take most patients off phlebotomy. VERIFY enrolled exactly that population: uncontrolled hematocrit despite standard care, still dependent on periodic blood removal.
A hormone the body already uses
Hepcidin was mapped in the early 2000s and named for its origins: the liver, and a side talent for killing microbes. Its central job turned out to be iron traffic control. Hepcidin binds and destroys ferroportin, the protein that exports iron from storage cells. More hepcidin means less iron reaching the marrow, which means fewer new red cells. Rusfertide is a synthetic copy of that lever.
Protagonist Therapeutics, a peptide specialist based in Newark, California, built the molecule and took it through a phase 2 program in which patients held hematocrit below 45% and some went more than two years without a phlebotomy. A paper in NEJM from that program described hepcidin agonists as a "chemical phlebotomy," which is the honest summary of the mechanism.
The phase 3 VERIFY study then randomized 293 phlebotomy-dependent patients to rusfertide plus standard of care or placebo plus standard of care. The primary endpoint was the share of patients who went from week 20 to week 32 without meeting the criteria for phlebotomy. Rusfertide delivered 76.9%; placebo, 32.9%. P < 0.0001.
The data held up at a year
Durability is where rare-disease approvals usually stumble, and this one did not. At 52 weeks, 84.1% of responders in the rusfertide arm kept their response. Patients who crossed over from placebo in part 1b responded too, at 77.9%. Mean hematocrit settled below 43%. The drug behaves like a maintenance therapy, not a transient effect.
The safety read is standard for a self-injected peptide. Injection-site reactions led the list, at 55.9% versus 32.9% on placebo; anemia followed at 15.9% versus 4.1%; fatigue was at parity. No grade 4 or 5 events appeared in the randomized portion. For a chronic disease whose alternative is a needle at a clinic every few weeks, that is a workable trade.
How the files moved
Topline phase 3 results landed in March 2025 and met the primary endpoint plus all four key secondary endpoints. The New Drug Application went to the FDA in January 2026. Priority review followed in March, setting a third-quarter action date. The approval came August 28, eight months after submission. Fast for a first-in-class mechanism.
The commercial shape matters too. Protagonist designed the peptide and carried it through phase 3. Takeda holds exclusive global rights and now runs development and commercialization. The arrangement converts a decade of peptide chemistry into a marketed asset with a first-in-class label, which is the structure investors tend to reward when the label holds.
The other attack on the same inconvenience
Phlebotomy is being automated as well. As we wrote in August, a Danish hospital tested Aletta, a robotic device that draws blood without an operator, aimed at a worsening phlebotomist shortage. Robot at the arm, molecule in the bloodstream: two very different companies attacking the same weekly inconvenience. The robot removes the bottleneck. The drug removes the need.
What the approval changes
For patients, the practical shift is phlebotomy-free months and less fatigue; patient-reported outcomes in VERIFY improved as well. For the companies, PV is a niche market by oncology standards, an FDA-designated rare blood disorder, which is why the platform question matters more than launch revenue.
Hereditary hemochromatosis is the same problem in a different frame: the body absorbs too much iron, and standard care is again periodic blood removal. Protagonist has studied rusfertide in that disease. If the mechanism transfers, the revenue story stops being a single-indication story. A drug that replaces a procedure, in a disease class that depends on procedures, has a wide lane.
What to watch
Real-world phlebotomy-free rates 12 months after launch, against the 76.9% trial number.
Pricing and access for a chronic weekly injection in a rare blood disease.
The hemochromatosis program and whether the platform clears a second indication.
Sapablursen's phase 3 INTREPID trial, running in the same phlebotomy-dependent PV population.
The oldest treatment meets its successor
Bloodletting was the oldest tool in medicine, and phlebotomy is its institutional descendant. On August 28, the tool met a molecule that does the same job with a weekly injection, backed by a trial that put the switch on solid arithmetic. The cautious reading is standard for rare-disease drugs: small populations, pricing risk, durability still being measured outside a controlled study. The structural reading is larger. A platform that replaces a procedure with a drug, aimed at diseases that have never been short of procedures, has room.